Abstract:
Progress in medicine, anaesthesia and surgical techniques have reduced significantly immediate and early surgical mortality. On the other hand, intra-operative and post-operative survival have been limited in some cancers such as liver and pancreatic cancer. There has been no significant improvement in survival in pancreatic cancer outcome in the last 5 decades. This presentation will discuss current research that hopefully will make a difference.
This will include: neoadjuvant immunological approach, intraductal and endo-vascular RF ablation as well as post-operative cancer vaccines.
Biography:
Nagy is a founder and Head of R&D of MiNA Therapeutics. For over three decades. He has been at the forefront of clinical research and clinical practice in cancer. He pioneered the first clinical trial in the use of adenovirus and plasmid for the treatment of liver cancer, as well as the use of plasmid gene therapy in hydrodynamic gene delivery. Currently, he is driving the development of an saRNA drug (a new class of medicines) which is currently being trialed in patients with liver cancer in eight UK centres, and sites in Singapore and Taiwan (OUTREACH study, ClinicalTrials.gov ID NCT02716012) and in a second trial in patients with solid tumours (TIMEPOINT study, ClinicalTrials.gov ID NCT 04105335) in the UK, USA, Europe, Singapore and Taiwan. He has published widely in gene therapy, stem cell therapy, oligonucleotides, endoscopy and surgery. Previously he was founder and Chairman of EMcision Limited (acquired by Boston Scientific Inc in 2018). he is Lead Clinician and Head of the Department of HPB Surgery at Imperial College London.
